Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Conditions

• Ocular Hypertension
• Open Angle Glaucoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution — DRUG
  Investigational ophthalmic solution
• Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution — DRUG
  Commercially available ophthalmic solution

Study Details

This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Key Dates

Start date

Sep 2, 2025

Status verified

Apr 2026

Primary completion

Apr 6, 2026

Completion

Apr 6, 2026

Study Design

Enrollment

489 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Reformulated PG324
  One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months
• Active Comparator: PG324
  One drop of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months

Primary Outcome Measure

Mean Intraocular Pressure at each timepoint post-randomization [ Time Frame: Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours ]

Locations (30)

Find similar trials in Dothan, AL

Related Studies

• Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
  PHASE3 · Recruiting · Amneal Pharmaceuticals, LLC · Newport Beach, California
• Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
  Enrolling By Invitation · Iantrek, Inc. · Newport Beach, California
• A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
  PHASE1 · Recruiting · Amneal Pharmaceuticals, LLC · Bakersfield, California
• Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama